Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26633206 | 0.86 | EPHX2 (0.39) | HTTALDH1A1EPHX2BRD4 | |
| SCHEMBL18697150 | 0.80 | MAPT (0.47) | EPHX2LMNAMAPTPOLBNPC1 | |
| SCHEMBL7899809 | 0.79 | ALDH1A1 (0.58) | HTTALDH1A1SMN1; SMN2PIM1KMT2A | |
| SCHEMBL7220170 | 0.79 | EPHX2 (0.40) | EPHX2LMNAKMT2AMAPT | |
| SCHEMBL2199315 | 0.78 | KCNA5 (0.48) | HTTALDH1A1EPHX2LMNASMN1; SMN2 | |
| SCHEMBL7893855 | 0.77 | IRAK4 (0.51) | ALDH1A1EPHX2LMNASMN1; SMN2KMT2A | |
| SCHEMBL2144487 | 0.77 | ALDH1A1 (0.46) | HTTALDH1A1SMN1; SMN2PIM1KMT2A | |
| SCHEMBL29591513 | 0.76 | BRD4 (0.45) | HTTALDH1A1SMN1; SMN2PIM1BRD4 | |
| SCHEMBL3524236 | 0.76 | BRD4 (0.45) | HTTALDH1A1SMN1; SMN2PIM1BRD4 | |
| SCHEMBL12066726 | 0.75 | EPHX2 (0.37) | EPHX2LMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3153023-B1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3153023-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2705181-B1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012151562-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012148540-A1 | COMBINATION OF KANASE INHIBITORS AND USES THREOF | INTELLIKINE, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2010138488-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010051043-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051042-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | HTT 1353/4885ALDH1A1 982/4885EPHX2 2460/4885 |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | HTT 3635/4885ALDH1A1 4042/4885EPHX2 2063/4885 |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CDC25C, CCNC, CDC25B | HTT 2858/4885ALDH1A1 2340/4885EPHX2 2096/4885 |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | HTT 3635/4885ALDH1A1 4042/4885EPHX2 2063/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | HTT 933/4885ALDH1A1 1326/4885EPHX2 1007/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | HTT 985/4885ALDH1A1 4563/4885EPHX2 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.